Join the Suboxone group to help and get support from people like you.
Suboxone News
Opioids Can Be Continued in Cancer Patients With Nonmedical Stimulant Use
MONDAY, Sept. 11, 2023 – For patients with cancer-related pain and nonmedical stimulant use, opioids should be continued, monitoring increased, and tapering avoided, according to a study published...
Just 1 in 5 Americans Struggling With Opioid Misuse Gets Meds That Can Help
MONDAY, Aug. 7, 2023 – The U.S. opioid abuse epidemic wages on, and overdose deaths continue to rise, yet just 1 in 5 people receives potentially lifesaving medication such as methadone,...
FDA Medwatch Alert: FDA Warns About Dental Problems with Buprenorphine Medicines Dissolved in the Mouth to Treat Opioid Use Disorder and Pain
What safety concern is FDA announcing? The U.S. Food and Drug Administration (FDA) is warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the...
FDA Medwatch Alert: Opioid Pain Relievers or Medicines to Treat Opioid Use Disorder - FDA Recommends Health Care Professionals Discuss Naloxone with All Patients when Prescribing
ISSUE: FDA is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to add new recommendations about naloxone to the prescribing information....
FDA Approves Cassipa (buprenorphine and naloxone) Sublingual Film as Maintenance Treatment for Opioid Dependence
September 7, 2018 – The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications
ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...
FDA Approves Zubsolv for the Maintenance Treatment of Opioid Dependence
Uppsala, Sweden – July 4, 2013 – Orexo today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine/naloxone) sublingual tablet CIII. Zub...
Reckitt Benckiser Pharmaceuticals Inc. Announces FDA Approval of Two New Dosage Strengths of Suboxone Sublingual Film (C-III) for Maintenance Treatment of Opioid Dependence
RICHMOND, Va., Aug. 20, 2012 /PRNewswire/ – Reckitt Benckiser Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) approval of the 4 mg and 12 mg doses of Suboxone...
Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Approval for Suboxone (buprenorphine and naloxone) Sublingual Film C-III
Richmond, VA (31st August 2010) – Reckitt Benckiser Pharmaceuticals Inc. today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (...
Ask a question
To post your own question to this support group, sign in or create an account.